» Articles » PMID: 25065857

Uptake of Pre-exposure Prophylaxis, Sexual Practices, and HIV Incidence in Men and Transgender Women Who Have Sex with Men: a Cohort Study

Abstract

Background: The effect of HIV pre-exposure prophylaxis (PrEP) depends on uptake, adherence, and sexual practices. We aimed to assess these factors in a cohort of HIV-negative people at risk of infection.

Methods: In our cohort study, men and transgender women who have sex with men previously enrolled in PrEP trials (ATN 082, iPrEx, and US Safety Study) were enrolled in a 72 week open-label extension. We measured drug concentrations in plasma and dried blood spots in seroconverters and a random sample of seronegative participants. We assessed PrEP uptake, adherence, sexual practices, and HIV incidence. Statistical methods included Poisson models, comparison of proportions, and generalised estimating equations.

Findings: We enrolled 1603 HIV-negative people, of whom 1225 (76%) received PrEP. Uptake was higher among those reporting condomless receptive anal intercourse (416/519 [81%] vs 809/1084 [75%], p=0·003) and having serological evidence of herpes (612/791 [77%] vs 613/812 [75%] p=0·03). Of those receiving PrEP, HIV incidence was 1·8 infections per 100 person-years, compared with 2·6 infections per 100 person-years in those who concurrently did not choose PrEP (HR 0·51, 95% CI 0·26-1·01, adjusted for sexual behaviours), and 3·9 infections per 100 person-years in the placebo group of the previous randomised phase (HR 0·49, 95% CI 0·31-0·77). Among those receiving PrEP, HIV incidence was 4·7 infections per 100 person-years if drug was not detected in dried blood spots, 2·3 infections per 100 person-years if drug concentrations suggested use of fewer than two tablets per week, 0·6 per 100 person-years for use of two to three tablets per week, and 0·0 per 100 person-years for use of four or more tablets per week (p<0·0001). PrEP drug concentrations were higher among people of older age, with more schooling, who reported non-condom receptive anal intercourse, who had more sexual partners, and who had a history of syphilis or herpes.

Interpretation: PrEP uptake was high when made available free of charge by experienced providers. The effect of PrEP is increased by greater uptake and adherence during periods of higher risk. Drug concentrations in dried blood spots are strongly correlated with protective benefit.

Funding: US National Institutes of Health.

Citing Articles

The mChoice App, an mHealth Tool for the Monitoring of Preexposure Prophylaxis Adherence and Sexual Behaviors in Young Men Who Have Sex With Men: Usability Evaluation.

Dos Santos F, Brin M, Tanner M, Galindo C, Schnall R JMIR Hum Factors. 2025; 12:e59780.

PMID: 40019786 PMC: 11887583. DOI: 10.2196/59780.


Awareness, willingness, and uptake of pre-exposure prophylaxis (PrEP) among men who have sex with men in Ghana.

Apreku A, Guure C, Dery S, Yakubu A, Abu-Baare G, Addo S BMC Infect Dis. 2025; 25(1):213.

PMID: 39948458 PMC: 11827451. DOI: 10.1186/s12879-025-10614-1.


Willingness to Use Long-Acting Injectable Pre-Exposure Prophylaxis among Adolescent Girls and Young Women in Kampala, Uganda.

Lunkuse J, Lwanga C, Wamono F, Muturi-Kioi V, Price M, Mayanja Y AIDS Behav. 2025; .

PMID: 39883369 DOI: 10.1007/s10461-025-04616-y.


Studying the Digital Intervention Engagement-Mediated Relationship Between Intrapersonal Measures and Pre-Exposure Prophylaxis Adherence in Sexual and Gender Minority Youth: Secondary Analysis of a Randomized Controlled Trial.

Williams M, Manjourides J, Smith L, Rainer C, Hightow-Weidman L, Haley D J Med Internet Res. 2025; 27:e57619.

PMID: 39804696 PMC: 11773288. DOI: 10.2196/57619.


Generalizing the intention-to-treat effect of an active control from historical placebo-controlled trials: A case study of the efficacy of daily oral TDF/FTC in the HPTN 084 study.

He Q, Gao F, Dukes O, Delany-Moretlwe S, Zhang B J Am Stat Assoc. 2025; 119(548):2478-2492.

PMID: 39749107 PMC: 11694715. DOI: 10.1080/01621459.2024.2360643.


References
1.
Donnell D, Baeten J, Bumpus N, Brantley J, Bangsberg D, Haberer J . HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr. 2014; 66(3):340-8. PMC: 4059553. DOI: 10.1097/QAI.0000000000000172. View

2.
Amico K, Stirratt M . Adherence to preexposure prophylaxis: current, emerging, and anticipated bases of evidence. Clin Infect Dis. 2014; 59 Suppl 1:S55-60. PMC: 4060253. DOI: 10.1093/cid/ciu266. View

3.
Amico K, McMahan V, Goicochea P, Vargas L, Marcus J, Grant R . Supporting study product use and accuracy in self-report in the iPrEx study: next step counseling and neutral assessment. AIDS Behav. 2012; 16(5):1243-59. DOI: 10.1007/s10461-012-0182-5. View

4.
Grohskopf L, Chillag K, Gvetadze R, Liu A, Thompson M, Mayer K . Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2013; 64(1):79-86. DOI: 10.1097/QAI.0b013e31828ece33. View

5.
Casey B, Jones R, Hare T . The adolescent brain. Ann N Y Acad Sci. 2008; 1124:111-26. PMC: 2475802. DOI: 10.1196/annals.1440.010. View